Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Judy who wrote (4273)	7/12/1998 9:43:00 PM
From: Nancy	Read Replies (1) \| Respond to of 9523

yes, fast track review status granted in 05/98. i picked up a little bit in recent retreat. here is some interesting twist : AHP owns 60% IMNX and has been funding IMNX research. Now AHP merges with MTC, they already changed some contractual agreements with IMNX, but Enbrel agreement is not touched. PFE doesn't develop Celebral itself, it is from a sub of MTC. PFE has signed the marketing license, and will handle all the FDA filings etc. (sort of like the agreement between SGP & ICN regarding the Hep. C drug). Now MTC will be part of AHP, how would that affect the agreement ? interesting. btw, MTC really causes DD some pain lately.